DE60123138D1 - Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs - Google Patents

Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs

Info

Publication number
DE60123138D1
DE60123138D1 DE60123138T DE60123138T DE60123138D1 DE 60123138 D1 DE60123138 D1 DE 60123138D1 DE 60123138 T DE60123138 T DE 60123138T DE 60123138 T DE60123138 T DE 60123138T DE 60123138 D1 DE60123138 D1 DE 60123138D1
Authority
DE
Germany
Prior art keywords
treatment
steroid
progesterone receptor
breast cancer
resistant breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60123138T
Other languages
English (en)
Other versions
DE60123138T2 (de
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051609A external-priority patent/DE10051609A1/de
Application filed by Schering AG filed Critical Schering AG
Publication of DE60123138D1 publication Critical patent/DE60123138D1/de
Application granted granted Critical
Publication of DE60123138T2 publication Critical patent/DE60123138T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60123138T 2000-10-18 2001-10-17 Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs Expired - Fee Related DE60123138T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609 2000-10-18
US241010P 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en) 2000-10-18 2001-10-17 Use of inhibitors of progesterone receptor for treating cancer

Publications (2)

Publication Number Publication Date
DE60123138D1 true DE60123138D1 (de) 2006-10-26
DE60123138T2 DE60123138T2 (de) 2007-09-13

Family

ID=26007397

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123138T Expired - Fee Related DE60123138T2 (de) 2000-10-18 2001-10-17 Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs

Country Status (26)

Country Link
EP (1) EP1414465B1 (de)
JP (1) JP4335525B2 (de)
KR (1) KR20030044006A (de)
CN (1) CN1311833C (de)
AT (1) ATE339208T1 (de)
AU (2) AU1595802A (de)
BG (1) BG107745A (de)
BR (1) BR0114677A (de)
CA (1) CA2423013A1 (de)
CY (1) CY1106289T1 (de)
CZ (1) CZ299945B6 (de)
DE (1) DE60123138T2 (de)
DK (1) DK1414465T3 (de)
EA (1) EA005945B1 (de)
EE (1) EE200300156A (de)
ES (1) ES2272561T3 (de)
HK (1) HK1071697A1 (de)
HR (1) HRP20030386A2 (de)
HU (1) HUP0301461A3 (de)
IL (2) IL154974A0 (de)
MX (1) MXPA03002953A (de)
NO (1) NO20031745D0 (de)
NZ (1) NZ545965A (de)
PL (1) PL366415A1 (de)
SK (1) SK4752003A3 (de)
WO (1) WO2002032429A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) * 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
FR2789393B1 (fr) * 1999-02-05 2001-10-12 Centre Nat Rech Scient Lactol steroidique

Also Published As

Publication number Publication date
ATE339208T1 (de) 2006-10-15
EE200300156A (et) 2003-08-15
HUP0301461A3 (en) 2010-01-28
NZ545965A (en) 2007-09-28
NO20031745L (no) 2003-04-15
EA200300468A1 (ru) 2003-10-30
HRP20030386A2 (en) 2005-04-30
CY1106289T1 (el) 2011-10-12
DE60123138T2 (de) 2007-09-13
EA005945B1 (ru) 2005-08-25
BG107745A (bg) 2004-01-30
JP4335525B2 (ja) 2009-09-30
CA2423013A1 (en) 2002-04-25
AU1595802A (en) 2002-04-29
AU2002215958B2 (en) 2006-08-17
IL154974A0 (en) 2003-10-31
MXPA03002953A (es) 2003-08-07
HUP0301461A2 (hu) 2003-10-28
JP2004513094A (ja) 2004-04-30
NO20031745D0 (no) 2003-04-15
ES2272561T3 (es) 2007-05-01
IL154974A (en) 2007-05-15
EP1414465B1 (de) 2006-09-13
PL366415A1 (en) 2005-01-24
WO2002032429A2 (en) 2002-04-25
CZ299945B6 (cs) 2008-12-29
BR0114677A (pt) 2003-10-07
SK4752003A3 (en) 2003-10-07
CN1311833C (zh) 2007-04-25
HK1071697A1 (en) 2005-07-29
AU2002215958C1 (en) 2002-04-29
KR20030044006A (ko) 2003-06-02
EP1414465A2 (de) 2004-05-06
DK1414465T3 (da) 2007-01-29
WO2002032429A3 (en) 2004-02-19
CN1551772A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
ATE266031T1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE410235T1 (de) Behandlung von ballastwasser
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE69935156D1 (de) hCG THERAPIE ZUR BEHANDLUNG VON METASTATISCHEM BRUSTKREBS
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE521351T1 (de) Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE10193322D2 (de) Verwendung von Protonenpumpen-Hemmern zur Behandlung von Erkrankungen des Bewegungsapparates
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8339 Ceased/non-payment of the annual fee